Director/PDMR Shareholding

Theracryf

22/05/2025 12:22

RNS Number : 8241J

Theracryf PLC

22 May 2025

 

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Director/PDMR Dealings

 

Alderley Park, UK - 22 May 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology confirms that following a transfer on 21 May 2025, Northern Standard Limited, a company that Non-Executive Director, Ed Wardle, has a 49 per cent interest in now owns 422,727,272 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares"). As a result, Mr Wardle is deemed to have a beneficial interest in 422,727,272 Ordinary Shares, representing 19.67 per cent. of the Company's Ordinary Shares.

The Ordinary Shares were transferred by Tracarta Limited, of which Northern Standard Limited is 51 per cent. owned a subsidiary. Following the above transfer Tracarta Limited has no direct holding in the Company.

 

The notification set out below is provided in accordance with the requirements of MAR.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Mr Edward Wardle
2
Reason for notification
a.
Position/Status
Non-Executive Director
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
TheraCryf plc
b.
LEI
213800NO3E6TSTQO8K20
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

 Identification Code
Ordinary Shares of 0.25p each
GB00BSVYN304
b.
Nature of the transaction
Transfer of Ordinary Shares to Northern Standard Limited, a company that Ed Wardle has 49% ownership of.
c.
Price(s) and volume(s)
Price:£0.0025
Volume: 422,727,272
d.
Aggregated information
- Aggregated Volume
- Price
See above
e.
Date of the transaction
21 May 2025
f.
Place of the transaction
Outside a trading venue


 

Enquiries

TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
+44 (0)1625 315 090
enquiries@theracryf.com
Turner Pope Investments (Joint Broker)
James Pope / Andy Thacker
Cavendish Capital Markets (NOMAD & Joint Broker)Geoff Nash / Teddy Whiley (Corporate Finance)
 Nigel Birks / Harriet Ward (ECM)
+44 (0)20 3657 0050
+44 (0)20 7220 0500
Vigo Consulting
Rozi Morris
+44 (0)20 7390 0231
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is a clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders.  The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHEAFSAAAFSEFA